Remifentanil 2mg Powder For Concentrate For Solution For Injection Or Infusion
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Remifentanil 2 mg powder for concentrate for solution for injection or infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One vial contains 2 mg remifentanil (as hydrochloride).
After reconstitution the solution contains 1 mg/ml of remifentanil (as hydrochloride), if prepared as recommended (see section 6.6).
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder for concentrate for solution for injection or infusion.
White to off white powder.
pH of the reconstituted solution: 2.5 to 3.5.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Remifentanil is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia.
Remifentanil is indicated for provision of analgesia in mechanically ventilated intensive care patients 18 years of age and over.
4.2 Posology and method of administration
Remifentanil shall be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function, and by persons specifically trained in the use of anaesthetic drugs and the recognition and management of the expected adverse effects of potent opioids, including
respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.
Continuous infusions of Remifentanil must be administered by a calibrated infusion device into a fast flowing IV line or via a dedicated I.V. line.
This infusion line should be connected at, or close to, the venous cannula and primed, to minimise the potential dead space (see section 6.6).
Remifentanil may also be given by target-controlled infusion (TCI) with an approved infusion device incorporating the Minto pharmacokinetic model with covariates for age and lean body mass (LBM) (Anesthesiology 1997; 86: 10-23).
Care should be taken to avoid obstruction or disconnection of infusion lines and to adequately clear the lines to remove residual Remifentanil after use (see section 4.4).
Remifentanil is for intravenous use only and must not be administered by epidural or intrathecal injection (see section 4.3).
Dilution
Remifentanil may be further diluted after reconstitution (see sections 6.3 and 6.6).
For manually-controlled infusion Remifentanil can be diluted to concentrations of 20 to 250 pg/ml (50 pg/ml is the recommended dilution for adults and 20 to 25 pg/ml for paediatric patients aged 1 year and over).
For TCI the recommended dilution of Remifentanil is 20 to 50 pg/ml.
General anaesthesia
The administration of Remifentanil must be individualised based on the patient’s response.
Adults
Administration by Manually-Controlled Infusion
The following table summarises the starting injection/infusion rates and dose range:
Dosing Guidelines for Adults
|
INDICATION |
BOLUS INJECTION (Pg/kg) |
CONTINUOUS INFUSION (Pg/kg/min) | |
|
Starting Rate |
Range | ||
|
Induction of anaesthesia Maintenance of anaesthesia in ventilated patients |
1 (give over not less than 30 seconds) |
0.5 to 1 | |
|
• Nitrous oxide (66%) |
0.5 to 1 |
0.4 |
0.1 to 2 |
|
• Isoflurane (starting dose 0.5 MAC) |
0.5 to 1 |
0.25 |
0.05 to 2 |
|
• Propofol (starting dose 100 pg/kg/min) |
0.5 to 1 |
0.25 |
0.05 to 2 |
When given by slow bolus injection Remifentanil shall be administered over not less than 30 seconds.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia (see Concomitant medication).
No data are available for dosage recommendations for simultaneous use of other hypnotics other than those listed in the table with remifentanil.
Induction of anaesthesia:
Remifentanil should be administered with a standard dose of hypnotic agent, such as propofol, thiopental, or isoflurane, for the induction of anaesthesia.
Administering Remifentanil after a hypnotic agent will reduce the incidence of muscle rigidity.
Remifentanil can be administered at an infusion rate of 0.5 to 1 pg/kg/min, with or without an initial slow bolus injection of 1 pg/kg given over not less than 30 seconds. If endotracheal intubation is to occur more than 8 to 10 minutes after the start of the infusion of Remifentanil, then a bolus injection is not necessary.
Maintenance of anaesthesia in ventilated patients:
After endotracheal intubation, the infusion rate of Remifentanil should be decreased, according to anaesthetic technique, as indicated in the above table.
Due to the fast onset and short duration of action of Remifentanil, the rate of administration during anaesthesia can be titrated upward in 25% to 100% increments or downward in 25% to 50% decrements, every 2 to 5 minutes to attain the desired level of p-opioid response.
In response to light anaesthesia, supplemental slow bolus injections may be administered every 2 to 5 minutes.
Anaesthesia in spontaneously breathing anaesthetised patients with a secured airway (e.g. laryngeal mask anaesthesia):
In spontaneously breathing anaesthetised patients with a secured airway respiratory depression is likely to occur. There is also a risk that muscle rigidity may occur. Therefore attention must be given to respiratory effects eventually combined with muscular rigidity. Special care is needed to adjust the dose to the patient requirements and ventilatory support and/or urgent intubation may be required. Adequate facilities should be available for monitoring of patients administered Remifentanil. It is essential that these facilities be fully equipped to handle all degrees of respiratory depression including intubation and/or muscle rigidity (see section 4.4).
The recommended starting infusion rate for supplemental analgesia in spontaneously breathing anaesthetised patients is 0.04 pg/kg/min with titration to effect.
A range of infusion rates from 0.025 to 0.1 pg/kg/min has been studied.
Bolus injections are not recommended in spontaneously breathing anaesthetised patients.
Remifentanil should not be used as an analgesic in procedures where patients remain conscious or do not receive any airway support during the procedure.
Concomitant medication:
Remifentanil decreases the amounts or doses of inhaled anaesthetics, hypnotics and benzodiazepines required for anaesthesia (see section 4.5).
Doses of the following agents used in anaesthesia: isoflurane, thiopentone, propofol and temazepam have been reduced by up to 75% when used concurrently with remifentanil.
Guidelines for discontinuation/continuation into the immediate post-operative period:
Due to the very rapid offset of action of Remifentanil no residual opioid activity will be present within 5 to 10 minutes after discontinuation.
For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of Remifentanil.
Sufficient time must be allowed to reach the maximum effect of the longer acting analgesic.
The choice of analgesic should be appropriate for the patient’s surgical procedure and the level of post-operative care.
In the event that longer acting analgesia has not been established prior to the end of surgery, Remifentanil may need to be continued to maintain analgesia during the immediate post-operative period until longer acting analgesia has reached its maximum effect.
Guidance on use in mechanically ventilated intensive care patients is provided in section Use in intensive care.
In patients who are breathing spontaneously, the infusion rate of Remifentanil should initially be decreased to a rate of 0.1 pg/kg/min. The infusion rate may then be increased or decreased by not greater than 0.025 pg/kg/min every five minutes, to balance the patient’s level of analgesia and respiratory rate.
Remifentanil should only be used in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function, under the close supervision of persons specifically trained in the recognition and management of the respiratory effects of potent opioids.
The use of bolus injections of Remifentanil to treat pain during the post-operative period is not recommended in patients who are breathing spontaneously.
Administration by Target-Controlled Infusion
Induction and maintenance of anaesthesia in ventilated patients:
Remifentanil TCI should be used in association with an intravenous or inhalational hypnotic agent during the induction and maintenance of anaesthesia in ventilated adult patients (see Table in section Adults).
In association with these agents, adequate analgesia for induction of anaesthesia and surgery can generally be achieved with target blood remifentanil concentrations ranging from 3 to 8 ng/ml.
Remifentanil should be titrated to individual patient response.
For particularly stimulating surgical procedures target blood concentrations up to 15 ng/ml may be required.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia (see Table and Concomitant medication subsection in Adults).
For information on blood remifentanil concentrations achieved with manually-controlled infusion see Table 6.
As there are insufficient data, the administration of Remifentanil by TCI for spontaneous ventilation anaesthesia is not recommended.
Guidelines for discontinuation/continuation into the immediate post-operative period:
At the end of surgery when the TCI infusion is stopped or the target concentration reduced, spontaneous respiration is likely to return at calculated remifentanil concentrations in the region of 1 to 2 ng/ml.
As with manually-controlled infusion, post-operative analgesia should be established before the end of surgery with longer acting analgesics (see Guidelines for discontinuation under Administration by manually-controlled infusion in section Adults.).
As there are insufficient data, the administration of Remifentanil by TCI for the management of post-operative analgesia is not recommended.
Paediatric patients (1 to 12 years of age)
Co-administration of Remifentanil and an intravenous anaesthetic agent for induction of anaesthesia has not been studied in detail and is therefore not recommended.
Remifentanil TCI has not been studied in paediatric patients and therefore administration of Remifentanil by TCI is not recommended in these patients.
The following doses of Remifentanil are recommended for maintenance of anaesthesia:
|
Dosing Guidelines for Paediatric Patients (1 to |
2 years of age) | ||
|
*CONCOMITANT |
BOLUS |
CONTINUOUS INFUSION | |
|
ANAESTHETIC AGENT |
INJECTION |
fUg /kg/min) | |
|
(PgW |
Starting Rate |
Typical Maintenance Rates | |
|
Halothane |
1 |
0.25 |
0.05 to 1.3 |
|
(starting dose 0.3 MAC) | |||
|
Sevoflurane |
1 |
0.25 |
0.05 to 0.9 |
|
(starting dose 0.3 MAC) | |||
|
Isoflurane |
1 |
0.25 |
0.06 to 0.9 |
|
(starting dose 0.5 MAC) | |||
*co-administered with nitrous oxide/oxygen in a ratio of 2:1
When given by bolus injection, Remifentanil should be administered over not less than 30 seconds.
Surgery should not commence until at least 5 minutes after the start of the Remifentanil infusion, if a simultaneous bolus dose has not been given.
For sole administration of nitrous oxide (70%) with Remifentanil, typical maintenance infusion rates should be between 0.4 and 3 pg/kg/min, and although not specifically studied, adult data suggest that 0.4 pg/kg/min is an appropriate starting rate.
Paediatric patients should be monitored and the dose titrated to the depth of analgesia appropriate for the surgical procedure.
Concomitant medication:
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane, halothane and sevoflurane should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia. No data are available for dosage recommendations for simultaneous use of other hypnotics other than those listed in the table with remifentanil (see section Adults - concomitant medication).
Guidelines for patient management in the immediate post-operative period
Establishment of alternative analgesia prior to discontinuation of Remifentanil:
Due to the very rapid offset of action of Remifentanil, no residual activity will be present within 5 to 10 minutes after discontinuation. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of Remifentanil. Sufficient time must be allowed to reach the therapeutic effect of the longer acting analgesic. The choice of agent(s), the dose and the time of administration should be planned in advance and individually tailored to be appropriate for the patient’s surgical procedure and the level of postoperative care anticipated (see section 4.4.).
Neonates/infants (aged less than 1 year)
There is limited clinical trial experience of remifentanil in neonates and infants (aged under 1 year old; see section 5.1). The pharmacokinetic profile of remifentanil in neonates/infants (aged less than 1 year) is comparable to that seen in adults after correction for body weight differences. (see section 5.2.). However, because there are insufficient clinical data, the administration of Remifentanil is not recommended for this age group.
Use for Total Intravenous anaesthesia (TIVA): There is limited clinical trial experience of remifentanil for TIVA in infants (see section 5.1). However, there are insufficient clinical data to make dosage recommendations.
Cardiac anaesthesia
Administration by Manually-Controlled Infusion
|
Dosing Guidelines for Cart |
iac Anaesthesia | ||
|
INDICATION |
BOLUS |
CONTINUOUS INFUSION | |
|
INJECTION |
(Mg/kg/min) | ||
|
(Mg/kg) |
Starting Rate |
Typical Infusion Rates | |
|
Induction Maintenance of anaesthesia |
Not recommended |
1 |
_ |
|
• Isoflurane (starting dose 0.4 MAC) |
0.5 to 1 |
1 |
0.003 to 4 |
|
• Propofol (starting dose 50 Mg/kg/min) |
0.5 to 1 |
1 |
0.01 to 4.3 |
|
Continuation of postoperative analgesia, prior to extubation |
Not recommended |
1 |
0 to 1 |
There are no sufficient data available on use in patients under 18 years of age undergoing cardiac surgery to establish dose recommendations for this population.
Remifentanil is not recommended for use in patients with poor left ventricular function (left ventricular ejection fraction less than 0.35), since the safe use of the product in this patient group has not been established.
Induction period of anaesthesia:
After administration of hypnotic to achieve loss of consciousness, Remifentanil should be administered at an initial infusion rate of 1 Mg/kg/min. The use of bolus injections of Remifentanil during induction in cardiac surgical patients is not recommended.
Endotracheal intubation should not occur until at least 5 minutes after the start of the infusion.
Maintenance period of anaesthesia:
After endotracheal intubation the infusion rate of Remifentanil should be titrated according to patient need. Supplemental slow bolus doses may also be given as required. High-risk cardiac patients, such as those with poor ventricular function or undergoing valve surgery, should be administered a maximum bolus dose of 0.5 pg/kg. These dosing recommendations also apply during hypothermic cardiopulmonary bypass (see section 5.2).
Concomitant medication:
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia.
No data are available for dosage recommendations for simultaneous use of other hypnotics other than those listed in the table with remifentanil (see section Adults -concomitant medication).
Guidelines for post-operative patient management
Continuation of Remifentanil post-operatively to provide analgesia prior to weaning for extubation:
It is recommended that the infusion of Remifentanil should be maintained at the final intra-operative rate during transfer of patients to the post-operative care area. Upon arrival into this area, the patient’s level of analgesia and sedation should be closely monitored and the Remifentanil infusion rate adjusted to meet the individual patient’s requirements (see section Use in intensive care for further information on management of intensive care patients).
Establishment of alternative analgesia prior to discontinuation of Remifentanil:
Due to the very rapid offset of action of Remifentanil, no residual opioid activity will be present within 5 to 10 minutes after discontinuation. Prior to discontinuation of Remifentanil, patients must be given alternative analgesic and sedative agents at a sufficient time in advance to allow the therapeutic effects of these agents to become established. It is therefore recommended that the choice of agent(s), the dose and the time of administration are planned, before weaning the patient from the ventilator.
Guidelines for discontinuation of Remifentanil:
Due to the very rapid offset of action of Remifentanil, hypertension, shivering and aches have been reported in cardiac patients immediately following discontinuation of Remifentanil (see section 4.8). To minimise the risk of these occurring, adequate alternative analgesia must be established (as described above), before the Remifentanil infusion is discontinued.
The infusion rate should be reduced by 25% decrements in at least 10 minute intervals until the infusion is discontinued.
During weaning from the ventilator the Remifentanil infusion should not be increased and only down titration should occur, supplemented as required with alternative analgesics.
Haemodynamic changes such as hypertension and tachycardia should be treated with alternative agents as appropriate.
When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the patient must be carefully monitored. The benefit of providing adequate post-operative analgesia must always be balanced against the potential risk of respiratory depression with these agents.
Administration by Target-Controlled Infusion Induction and maintenance of anaesthesia:
Remifentanil TCI should be used in association with an intravenous or inhalational hypnotic agent during the induction and maintenance of anaesthesia in ventilated adult patients (see Table in section Cardiac anaesthesia).
In association with these agents, adequate analgesia for cardiac surgery is generally achieved at the higher end of the range of target blood remifentanil concentrations used for general surgical procedures. Following titration of remifentanil to individual patient response, blood concentrations as high as 20 ng/ml have been used in clinical studies.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia (see Table and Concomitant medication subsection in Cardiac anaesthesia).
For information on blood remifentanil concentrations achieved with manually-controlled infusion see Table 6.
Guidelines for discontinuation/continuation into the immediate post-operative period:
At the end of surgery when the TCI infusion is stopped or the target concentration reduced, spontaneous respiration is likely to return at calculated remifentanil concentrations in the region of 1 to 2 ng/ml.
As with manually-controlled infusion, post-operative analgesia should be established before the end of surgery with longer acting analgesics (see Guidelines for discontinuation under Administration by manually-controlled infusion in section Cardiac anaesthesia).
As there are insufficient data, the administration of Remifentanil by TCI for the management of post-operative analgesia is not recommended.
Use in intensive care
Remifentanil can be used for the provision of analgesia in mechanically ventilated intensive care patients of 18 years of age and over. Sedative agents should be added as appropriate.
The safety and efficacy from well-controlled clinical trials of Remifentanil in mechanically ventilated intensive care patients has been established for durations up to 3 days (see section Renally impaired intensive care patients and section 5.2). Therefore, the use of Remifentanil is not recommended for a duration of treatment greater than 3 days.
Remifentanil TCI has not been studied in intensive care patients and therefore administration of Remifentanil by TCI is not recommended in these patients.
In adults, it is recommended that Remifentanil is initiated at an infusion rate of 0.1 pg/kg/min (6 pg/kg/h) to 0.15 pg/kg/min (9 pg/kg/h). The infusion rate should be titrated in increments of 0.025 pg/kg/min (1.5 pg/kg/h) to achieve the desired level of analgesia. A period of at least 5 minutes should be allowed between dose adjustments. The patient should be regularly assessed and the Remifentanil infusion rate adjusted accordingly.
If an infusion rate of 0.2 pg/kg/min (12 pg/kg/h) is reached and sedation is required, it is recommended that dosing with an appropriate sedative agent is initiated (see below). The dose of sedative agent should be titrated to obtain the desired level of sedation. Further increases to the Remifentanil infusion rate in increments of 0.025 pg/kg/min (1.5 pg/kg/h) may be made if additional analgesia is required.
The following table summarises the starting infusion rates and typical dose range for provision of analgesia in individual patients:
Dosing Guidelines for use of Remifentanil within the Intensive Care Setting
|
CONTINUOUS pg/kg/min ( |
INFUSION pg/kg/h) |
|
Starting Rate |
Range |
|
0.1(6) to 0.15 (9) |
0.006 (0.36) to 0.74 (44.4) |
Bolus doses of Remifentanil are not recommended in the intensive care setting.
The use of Remifentanil will reduce the dosage requirement of any concomitant sedative agents. Typical starting doses for sedative agents, if required, are given below.
Recommended starting dose of sedative agents, if required:
|
Sedative Agents |
Bolus (mg/kg) |
Infusion (mg/kg/h) |
|
Propofol |
Up to 0.5 |
0.5 |
|
Midazolam |
Up to 0.03 |
0.03 |
To allow separate titration of the respective agents, sedative agents should not be administered as an admixture.
Additional analgesia for ventilated patients undergoing stimulating procedures:
An increase in the existing Remifentanil infusion rate may be required to provide additional analgesic cover for ventilated patients undergoing stimulating and/or painful procedures such as endotracheal suctioning, wound dressing and physiotherapy.
It is recommended that a Remifentanil infusion rate of at least 0.1 pg/kg/min (6 pg/kg/h) should be maintained for at least 5 minutes prior to the start of the stimulating procedure.
Further dose adjustments may be made every 2 to 5 minutes in increments of 25% to 50% in anticipation of, or in response to, additional requirement for analgesia.
A mean infusion rate of 0.25 pg/kg/min (15 pg/kg/h), maximum 0.74 pg/kg/min (45 pg/kg/h), has been administered for provision of additional anaesthesia during stimulating procedures.
Establishment of alternative analgesia prior to discontinuation of Remifentanil:
Due to the very rapid offset of action of Remifentanil, no residual opioid activity will be present within 5 to 10 minutes after discontinuation regardless of the duration of infusion.
Following administration of Remifentanil, the possibility of tolerance and hyperalgesia should be considered. Therefore, prior to discontinuation of Remifentanil, patients must be given alternative analgesic and sedative agents to prevent hyperalgesia and associated haemodynamic changes.
These agents must be given at a sufficient time in advance to allow the therapeutic effects of these agents to become established. The range of options for analgesia includes long acting oral, intravenous, or regional analgesics controlled by the nurse or the patient. These techniques should always be titrated to individual patient needs as the infusion of Remifentanil is reduced. It is recommended that the choice of agent(s), the dose, and the time of administration are planned prior to discontinuation of Remifentanil.
There is a potential for the development of tolerance with time during prolonged administration of p-opioid agonists.
Guidelines for extubation and discontinuation of Remifentanil:
In order to ensure a smooth emergence from a Remifentanil based regimen it is recommended that the infusion rate of Remifentanil is titrated in stages to 0.1 pg/kg/min (6 pg/kg/h) over a period up to 1 hour prior to extubation.
Following extubation, the infusion rate should be reduced by 25% decrements in at least 10-minute intervals until the infusion is discontinued. During weaning from the ventilator the Remifentanil infusion should not be increased and only down titration should occur, supplemented as required with alternative analgesics.
Upon discontinuation of Remifentanil, the IV cannula should be cleared or removed to prevent subsequent inadvertent administration.
When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the patient must be carefully monitored. The benefit of providing adequate analgesia must always be balanced against the potential risk of respiratory depression with these agents.
Paediatric intensive care patients
The use of remifentanil in intensive care patients under the age of 18 years is not recommended as there are no data available in this patient population.
Renally-impaired intensive care patients
No adjustments to the doses recommended above are necessary in renally-impaired patients including those undergoing renal replacement therapy, however the clearance of the carboxylic acid metabolite is reduced in patients with renal impairment (see section 5.2).
Special patient populations Elderly (over 65 years of age)
General anaesthesia:
The initial starting dose of remifentanil administered to patients over 65 should be half the recommended adult dose and then shall be titrated to individual patient need as an increased sensitivity to the pharmacological effects of remifentanil has been seen in this patient population. This dose adjustment applies to use in all phases of anaesthesia including induction, maintenance, and immediate post-operative analgesia.
Because of the increased sensitivity of elderly patients to Remifentanil, when administering Remifentanil by TCI in this population the initial target concentration should be 1.5 to 4 ng/ml with subsequent titration to response.
Cardiac anaesthesia:
No initial dose reduction is required (see section Cardiac anaesthesia.).
Intensive Care:
No initial dose reduction is required (see section Use in intensive care.).
Obese patients
For manually-controlled infusion it is recommended that for obese patients the dosage of Remifentanil should be reduced and based upon ideal body weight as the clearance and volume of distribution of remifentanil are better correlated with ideal body weight than actual body weight.
With the calculation of lean body mass (LBM) used in the Minto model, LBM is likely to be underestimated in female patients with a body mass index (BMI) greater than 35 kg/m and in male patients with BMI greater than 40 kg/m . To avoid underdosing in these patients, remifentanil TCI should be titrated carefully to individual response.
Renal impairment
On the basis of investigations carried out to date, a dose adjustment in patients with impaired renal function, including intensive care patients, is not necessary.
Hepatic impairment
Studies carried out with a limited number of patients with impaired liver function, do not justify any special dosage recommendations. However, patients with severe
hepatic impairment may be slightly more sensitive to the respiratory depressant effects of remifentanil (see section 4.4).
These patients shall be closely monitored and the dose of remifentanil shall be titrated to individual patient need.
Neurosurgery
Limited clinical experience in patients undergoing neurosurgery has shown that no special dosage recommendations are required.
ASA III/IV patients
General anaesthesia:
As the haemodynamic effects of potent opioids can be expected to be more pronounced in ASA III/IV patients, caution should be exercised in the administration of Remifentanil in this population.
Initial dosage reduction and subsequent titration to effect is therefore recommended.
In paediatric patients, there are insufficient data to make a dosage recommendation. For TCI, a lower initial target of 1.5 to 4 ng/ml should be used in ASA III or IV patients and subsequently titrated to response.
Cardiac anaesthesia:
No initial dose reduction is required (see section Cardiac anaesthesia.).
The following tables give guidelines for infusion rates of Remifentanil for manually-controlled infusion:
Table 1._Remifentanil for Injection Infusion Rates (ml/kg/h)
|
Drug Delivery |
Infusion Delivery Rate (ml/kg/h) for Solution Concentrations of | |||
|
Rate (M-g/kg/min) |
20 Mg/ml 1 mg/50 ml |
25 Mg/ml 1 mg/40 ml |
50 Mg/ml 1 mg/20 ml |
250 Mg/ml 10 mg/40 ml |
|
0.0125 |
0.038 |
0.03 |
0.015 |
Not recommended |
|
0.025 |
0.075 |
0.06 |
0.03 |
Not recommended |
|
0.05 |
0.15 |
0.12 |
0.06 |
0.012 |
|
0.075 |
0.23 |
0.18 |
0.09 |
0.018 |
|
0.1 |
0.3 |
0.24 |
0.12 |
0.024 |
|
0.15 |
0.45 |
0.36 |
0.18 |
0.036 |
|
0.2 |
0.6 |
0.48 |
0.24 |
0.048 |
|
0.25 |
0.75 |
0.6 |
0.3 |
0.06 |
|
0.5 |
1.5 |
1.2 |
0.6 |
0.12 |
|
0.75 |
2.25 |
1.8 |
0.9 |
0.18 |
|
1.0 |
3.0 |
2.4 |
1.2 |
0.24 |
|
1.25 |
3.75 |
3.0 |
1.5 |
0.3 |
|
1.5 |
4.5 |
3.6 |
1.8 |
0.36 |
|
1.75 |
5.25 |
4.2 |
2.1 |
0.42 |
|
2.0 |
6.0 |
4.8 |
2.4 |
0.48 |
Table 2._Remifentanil for Injection Infusion Rates (ml/h) for a 20 [ig/ml Solution
|
Infusion Rate (ig/kg/min) |
Patient Weight (kg) | ||||||
|
5 |
10 |
20 |
30 |
40 |
50 |
60 | |
|
0.0125 |
0.188 |
0.375 |
0.75 |
1.125 |
1.5 |
1.875 |
2.25 |
|
0.025 |
0.375 |
0.75 |
1.5 |
2.25 |
3.0 |
3.75 |
4.5 |
|
0.05 |
0.75 |
1.5 |
3.0 |
4.5 |
6.0 |
7.5 |
9.0 |
|
0.075 |
1.125 |
2.25 |
4.5 |
6.75 |
9.0 |
11.25 |
13.5 |
|
0.1 |
1.5 |
3.0 |
6.0 |
9.0 |
12.0 |
15.0 |
18.0 |
|
0.15 |
2.25 |
4.5 |
9.0 |
13.5 |
18.0 |
22.5 |
27.0 |
|
0.2 |
3.0 |
6.0 |
12.0 |
18.0 |
24.0 |
30.0 |
36.0 |
|
0.25 |
3.75 |
7.5 |
15.0 |
22.5 |
30.0 |
37.5 |
45.0 |
|
0.3 |
4.5 |
9.0 |
18.0 |
27.0 |
36.0 |
45.0 |
54.0 |
|
0.35 |
5.25 |
10.5 |
21.0 |
31.5 |
42.0 |
52.5 |
63.0 |
|
0.4 |
6.0 |
12.0 |
24.0 |
36.0 |
48.0 |
60.0 |
72.0 |
Table 3._Remifentanil for Injection Infusion Rates (ml/h) for a 25 jg/ml Solution
|
Infusion Rate (ig/kg/min) |
Patient Weight ( |
kg) | ||||||||
|
10 |
20 |
30 |
40 |
50 |
60 |
70 |
80 |
90 |
100 | |
|
0.0125 |
0.3 |
0.6 |
0.9 |
1.2 |
1.5 |
1.8 |
2.1 |
2.4 |
2.7 |
3.0 |
|
0.025 |
0.6 |
1.2 |
1.8 |
2.4 |
3.0 |
3.6 |
4.2 |
4.8 |
5.4 |
6.0 |
|
0.05 |
1.2 |
2.4 |
3.6 |
4.8 |
6.0 |
7.2 |
8.4 |
9.6 |
10.8 |
12.0 |
|
0.075 |
1.8 |
3.6 |
5.4 |
7.2 |
9.0 |
10.8 |
12.6 |
14.4 |
16.2 |
18.0 |
|
0.1 |
2.4 |
4.8 |
7.2 |
9.6 |
12.0 |
14.4 |
16.8 |
19.2 |
21.6 |
24.0 |
|
0.15 |
3.6 |
7.2 |
10.8 |
14. A |
18.0 |
21.6 |
25.2 |
28.8 |
32.4 |
36.0 |
|
0.2 |
4.8 |
9.6 |
14.4 |
4 19. 2 |
24.0 |
28.8 |
33.6 |
38.4 |
43.2 |
48.0 |
Table 4._Remifentanil for Injection Infusion Rates (ml/h) for a 50 ig/ml Solution
|
Infusion Rate (ig/kg/min) |
Patient Weight (kg) | |||||||
|
30 |
40 |
50 |
60 |
70 |
80 |
90 |
100 | |
|
0.025 |
0.9 |
1.2 |
1.5 |
1.8 |
2.1 |
2.4 |
2.7 |
3.0 |
|
0.05 |
1.8 |
2.4 |
3.0 |
3.6 |
4.2 |
4.8 |
5.4 |
6.0 |
|
0.075 |
2.7 |
3.6 |
4.5 |
5.4 |
6.3 |
7.2 |
8.1 |
9.0 |
|
0.1 |
3.6 |
4.8 |
6.0 |
7.2 |
8.4 |
9.6 |
10.8 |
12.0 |
|
0.15 |
5.4 |
7.2 |
9.0 |
10.8 |
12.6 |
14.4 |
16.2 |
18.0 |
|
0.2 |
7.2 |
9.6 |
12.0 |
14.4 |
16.8 |
19.2 |
21.6 |
24.0 |
|
0.25 |
9.0 |
12.0 |
15.0 |
18.0 |
21.0 |
24.0 |
27.0 |
30.0 |
|
0.5 |
18.0 |
24.0 |
30.0 |
36.0 |
42.0 |
48.0 |
54.0 |
60.0 |
|
0.75 |
27.0 |
36.0 |
45.0 |
54.0 |
63.0 |
72.0 |
81.0 |
90.0 |
|
1.0 |
36.0 |
48.0 |
60.0 |
72.0 |
84.0 |
96.0 |
108.0 |
120.0 |
|
1.25 |
45.0 |
60.0 |
75.0 |
90.0 |
105.0 |
120.0 |
135.0 |
150.0 |
|
1.5 |
54.0 |
72.0 |
90.0 |
108.0 |
126.0 |
144.0 |
162.0 |
180.0 |
|
1.75 |
63.0 |
84.0 |
105.0 |
126.0 |
147.0 |
168.0 |
189.0 |
210.0 |
|
2.0 |
72.0 |
96.0 |
120.0 |
144.0 |
168.0 |
192.0 |
216.0 |
240.0 |
Table 5._Remifentanil for Injection Infusion Rates (ml/h) for a 250 ig/ml Solution
|
Infusion Rate (ig/kg/min) |
Patient Weight (kg) | |||||||
|
30 |
40 |
50 |
60 |
70 |
80 |
90 |
100 | |
|
0.1 |
0.72 |
0.96 |
1.20 |
1.44 |
1.68 |
1.92 |
2.16 |
2.40 |
|
0.15 |
1.08 |
1.44 |
1.80 |
2.16 |
2.52 |
2.88 |
3.24 |
3.60 |
|
0.2 |
1.44 |
1.92 |
2.40 |
2.88 |
3.36 |
3.84 |
4.32 |
4.80 |
|
0.25 |
1.80 |
2.40 |
3.00 |
3.60 |
4.20 |
4.80 |
5.40 |
6.00 |
|
0.5 |
3.60 |
4.80 |
6.00 |
7.20 |
8.40 |
9.60 |
10.80 |
12.00 |
|
0.75 |
5.40 |
7.20 |
9.00 |
10.80 |
12.60 |
14.40 |
16.20 |
18.00 |
|
1.0 |
7.20 |
9.60 |
12.00 |
14.40 |
16.80 |
19.20 |
21.60 |
24.00 |
|
1.25 |
9.00 |
12.00 |
15.00 |
18.00 |
21.00 |
24.00 |
27.00 |
30.00 |
|
1.5 |
10.80 |
14.40 |
18.00 |
21.60 |
25.20 |
28.80 |
32.40 |
36.00 |
|
1.75 |
12.60 |
16.80 |
21.00 |
25.20 |
29.40 |
33.60 |
37.80 |
42.00 |
|
2.0 |
14.40 |
19.20 |
24.00 |
28.80 |
33.60 |
38.40 |
43.20 |
48.00 |
The following table provides the equivalent blood remifentani
concentration using a
TCI approach for various manually-controlled infusion rates at steady state:
Table 6. Remifentanil Blood Concentrations (ng/ml) estimated using the Minto (1997) Pharmacokinetic Model in a 70 kg, 170 cm, 40 Year Old Male Patient for Various Manually-Controlled Infusion rates (ig/kg/min) at _Steady State.__
|
Remifentanil Infusion Rate |
Remifentanil Blood Concentration |
|
(ig/kg/min) |
(ng/ml) |
|
0.05 |
1.3 |
|
0.10 |
2.6 |
|
0.25 |
6.3 |
|
0.40 |
10.4 |
|
0.50 |
12.6 |
|
1.0 |
25.2 |
|
2.0 |
50.5 |
4.3 Contraindications
As glycine is present in the formulation, Remifentanil is contra-indicated for epidural and intrathecal use (see section 5.3).
Remifentanil is contra-indicated in patients with hypersensitivity to the active substance or other fentanyl analogues or to any of the excipients.
Remifentanil is contra-indicated for use as the sole agent for induction of anaesthesia.
4.4
Special warnings and precautions for use
Remifentanil shall be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function, and by persons specifically trained in the use of anaesthetic drugs and the recognition and management of the expected adverse effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.
The use of Remifentanil in mechanically ventilated intensive care patients is not recommended for a duration of treatment greater than 3 days.
Rapid offset of action/Transition to alternative analgesia
Due to the very rapid offset of action of Remifentanil, no residual opioid activity will be present within 5 to 10 minutes after the discontinuation of Remifentanil.
For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of Remifentanil.
The possibility of tolerance, hyperalgesia and associated haemodynamic changes should be considered when used in Intensive Care Unit.
Prior to discontinuation of Remifentanil, patients must be given alternative analgesic and sedative agents. Sufficient time must be allowed to reach the therapeutic effect of the longer acting analgesic. The choice of agent(s), the dose and the time of administration should be planned in advance and individually tailored to be appropriate for the patient’s surgical procedure and the level of post-operative care anticipated. When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the benefit of providing adequate post-operative analgesia must always be balanced against the potential risk of respiratory depression with these agents.
Discontinuation of treatment
Common post-operative events associated with the emergence from general anaesthesia, such as shivering, agitation, tachycardia, hypertension, may occur earlier following discontinuation of Remifentanil.
Symptoms following withdrawal of remifentanil including tachycardia, hypertension and agitation have been reported infrequently upon abrupt cessation, particularly after prolonged administration of more than 3 days. Where reported, re-introduction and tapering of the infusion has been beneficial. The use of Remifentanil in mechanically ventilated intensive care patients is not recommended for duration of treatment greater than 3 days.
Muscle rigidity - prevention and management
At the doses recommended muscle rigidity, sometimes severe, may occur. As with other opioids, the incidence of muscle rigidity is related to the dose and rate of administration. Therefore, slow bolus injections shall be administered over not less than 30 seconds.
Muscle rigidity induced by remifentanil must be treated in the context of the patients clinical condition with appropriate supporting measures. Excessive muscle rigidity occurring during the induction of anaesthesia should be treated by the administration of a neuromuscular blocking agent and/or additional hypnotic agents. Muscle rigidity seen during the use of remifentanil as an analgesic may be treated by stopping or decreasing the rate of administration of remifentanil.
Resolution of muscle rigidity after discontinuing the infusion of remifentanil occurs within minutes.
Alternatively an opioid antagonist may be administered, however this may reverse or attenuate the analgesic effect of remifentanil.
Respiratory depression - prevention and management
As with all potent opioids, profound analgesia is accompanied by marked respiratory depression. There are reports of patients with delayed respiratory depression 20-30 minutes after the remifentanil infusion has been discontinued. Therefore, remifentanil shall only be used in areas where facilities for monitoring and dealing with respiratory depression are available. Special care should be taken in patients with respiratory dysfunction. The appearance of respiratory depression shall be managed appropriately, including decreasing the rate of infusion by 50%, or a temporary discontinuation of the infusion. Unlike other fentanyl analogues, remifentanil has not been shown to cause recurrent respiratory depression, even after prolonged administration. However, as many factors may affect post-operative recovery it is important to ensure that full consciousness and adequate spontaneous ventilation are achieved before the patient is discharged from the recovery area.
Cardiovascular effects
The risk of cardiovascular effects such as hypotension and bradycardia, which may rarely lead to asystole/cardiac arrest (see sections 4.5 and 4.8) may be reduced by lowering the rate of infusion of Remifentanil or the dose of concurrent anaesthetics or by using IV fluids, vasopressor or anticholinergic agents as appropriate.
Debilitated, hypovolaemic, hypotensive and elderly patients may be more sensitive to the cardiovascular effects of remifentanil.
Inadvertent administration
A sufficient amount of Remifentanil may be present in the dead space of the IV line and/or cannula to cause respiratory depression, apnoea and/or muscle rigidity if the line is flushed with IV fluids or other drugs. This may be avoided by administering Remifentanil into a fast flowing IV line or via a dedicated IV line, which is removed when Remifentanil is discontinued.
Neonates/infants
There is limited data available on use in neonates/infants under 1 year of age (see sections 4.2 - Neonates/infants (aged less than 1 year) and 5.1).
Drug abuse
As with other opioids remifentanil may produce dependency.
Athletes
This medicine contains an active substance that may give a positive result in antidoping tests.
4.5 Interaction with other medicinal products and other forms of interaction
Remifentanil is not metabolised by plasmacholinesterase, therefore, interactions with drugs metabolised by this enzyme are not anticipated.
As with other opioids, remifentanil, whether given by manually-controlled infusion or TCI, decreases the doses of inhaled and IV anaesthetics, and benzodiazepines required for anaesthesia (see section 4.2). If doses of concomitantly administered CNS depressant drugs are not reduced, patients may experience an increased incidence of adverse effects associated with these agents.
Information of drug interactions with other opioids in relation to anaesthesia is very limited.
The cardiovascular effects of Remifentanil (hypotension and bradycardia - see sections 4.4 and 4.8), may be exacerbated in patients receiving concomitant cardiac depressant drugs, such as beta-blockers and calcium channel blocking agents.
4.6 Pregnancy and lactation
There are no adequate and well-controlled studies in pregnant women.
In a human clinical trial, the concentration of remifentanil in foetal blood was approximately 50% of that in maternal blood. The foetal arterio-venous ratio of remifentanil concentrations was approximately 30%, suggesting metabolism of remifentanil in the new born infant.
Remifentanil should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
It is not known whether remifentanil is excreted in human milk. However, because fentanyl analogues are excreted in human milk and
remifentanil-related material was found in rat milk after dosing with remifentanil, nursing mothers should be advised to discontinue breast feeding for 24 hours following administration of remifentanil.
Labour and delivery
There are insufficient data to recommend remifentanil for use during labour and caesarean section. It is known that remifentanil crosses the placental barrier and fentanyl analogues can cause respiratory depression in the child.
For a summary of the reproductive toxicity study findings please refer to Section 5.3.
4.7 Effects on ability to drive and use machines
After anaesthesia with remifentanil the patient should not drive or operate machinery. The physician should decide when these activities may be resumed. It is advisable that the patient is accompanied when returning home and that alcoholic drink is avoided.
This medicine can impair cognitive function and can affect a patient’s ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called ‘statutory defence’) if:
o The medicine has been prescribed to treat a medical or dental problem and o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and o It was not affecting your ability to drive safely
4.8 Undesirable effects
The most common undesirable effects associated with remifentanil are direct extensions of p-opioid agonist pharmacology. These adverse events resolve within minutes of discontinuing or decreasing the rate of remifentanil administration.
The frequencies below are defined as very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1,000 to <1/100), rare (>1/10,000 to <1/1,000) to very rare (<1/10,000).
Immune System Disorders
Rare: Allergic reactions including anaphylaxis
have been reported in patients receiving remifentanil in conjunction with one or more anaesthetic agents.
Nervous System Disorders
Very common: Skeletal muscle rigidity
Rare: Sedation (during recovery from general
anaesthesia)
Cardiac Disorders
Common:
Rare:
Vascular Disorders
Very common: Common:
Bradycardia
Asystole/cardiac arrest, usually preceded by bradycardia, has been reported in patients receiving remifentanil in conjunction with other anaesthetic agents.
Hypotension
Post-operative hypertension
Respiratory, Thoracic and Mediastinal Disorders
Common: Acute respiratory depression, apnoea
Uncommon: Hypoxia
Gastrointestinal Disorders
Nausea, vomiting Constipation
Very common:
Uncommon:
Skin and Subcutaneous Tissue Disorders
Common: Pruritus
General Disorders and Administration Site Conditions
Common: Post-operative shivering
Uncommon: Post-operative aches
4.9 Overdose
As with all potent opioid analgesics, overdose would be manifested by an extension of the pharmacologically predictable actions of remifentanil.
Due to the very short duration of action of Remifentanil, the potential for deleterious effects due to overdose are limited to the immediate time period following drug administration. Response to discontinuation of the drug is rapid, with return to baseline within ten minutes.
In the event of overdose or suspected overdose, take the following actions: discontinue administration of Remifentanil, maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function. If depressed respiration is associated with muscle rigidity, a neuromuscular blocking agent may be required to facilitate assisted or controlled respiration.
Intravenous fluids and vasopressor for the treatment of hypotension and other supportive measures may be employed.
Intravenous administration of an opioid antagonist such as naloxone may be given as a specific antidote to manage severe respiratory depression and muscle rigidity. The duration of respiratory depression following overdose with Remifentanil is unlikely to exceed the duration of action of the opioid antagonist.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Opioid anaesthetics, ATC code: N01A H06.
Remifentanil is a selective ^-opioid agonist with a rapid onset and very short duration of action. The ^-opioid activity of remifentanil is antagonised by narcotic antagonists, such as naloxone.
Assays of histamine in patients and normal volunteers have shown no elevation in histamine levels after administration of remifentanil in bolus doses up to 30pg/kg.
Neonates/infants (aged less than 1 year):
In a randomised (ratio of 2:1, remifentanil:halothane), open label, parallel group, multicentre study in 60 young infants and neonates <8 weeks of age (mean 5.5 weeks) with an ASA physical status of I-II who were undergoing pyloromyotomy, the efficacy and safety of remifentanil (given as a 0.4 pg/kg/min initial continuous infusion plus supplemental doses or infusion rate changes as needed) was compared with halothane (given at 0.4% with supplemental increases as needed). Maintenance of anaesthesia was achieved by the additional administration of 70% nitrous oxide (N20) plus 30% oxygen. Recovery times were superior in the remifentanil relative to the halothane groups (not significant). Use for Total Intravenous anaesthesia (TIVA) -children aged 6 months to 16 years TIVA with remifentanil in paediatric surgery was compared to inhalation anaesthesia in three randomised, open-label studies. The results are summarised in the table below.
|
Surgical intervention |
Age (y^ (N) |
Study condition (maintenance) |
Extubation (min) |
|
Lower abdominal/urological surgery |
0.5-16 (120) |
TIVA: propofol (5 -10 mg/kg/h) + reminfentanil (0.125 - 1.0 pg/kg/min) |
11.8 (4.2) |
|
Inhalation anaesthesia: sevoflurane (1.0 -1.5 MAC) and remifentanil (0.125 - 1.0 pg/kg/min) |
15.0 (5.6) (p<0.05) | ||
|
ENT-surgery |
4-11 (50) |
TIVA: propofol (3 mg/kg/h) + remifentanil (0.5 pg/kg/min) |
11 (3.7) |
|
Inhalation anaesthesia: desflurane (1.3 MAC) and N2O mixture |
9.4 (2.9) Not significant | ||
|
General or ENT surgery |
2-12 (153) |
TIVA: remifentanil (0.2 - 0.5 pg/kg/min) + propofol (100 -200 pg/kg/min) |
Comparable extubation times (based on limited data) |
|
Inhalation anaesthesia: sevoflurane (1 -1.5 MAC) + N2O mixture |
In the study in lower abdominal/urological surgery comparing remifentanil/propofol with remifentanil/sevoflurane, hypotension occurred significantly more often under remifentanil/sevoflurane, and bradycardia occurred significantly more often under remifentanil/propofol. In the study in ENT surgery comparing remifentanil/propofol with desflurane/nitrous oxide, a significantly higher heart rate was seen in subjects receiving desflurane/nitrous oxide compared with remifentanil/propofol and with baseline values.
5.2 Pharmacokinetic properties
Following administration of the recommended doses of remifentanil, the effective half-life is 3 to 10 minutes. The average clearance of remifentanil in young healthy adults is 40 ml/min/kg, the central volume of distribution is 100 ml/kg, and the steady-state volume of distribution is 350 ml/kg. Blood concentrations of remifentanil are proportional to the dose administered throughout the recommended dose range. For every 0.1 pg/kg/min increase in infusion rate, the blood concentration of remifentanil will rise 2.5 ng/ml. Remifentanil is approximately 70% bound to plasma proteins.
Metabolism
Remifentanil is an esterase metabolised opioid that is susceptible to metabolism by non-specific blood and tissue esterases. The metabolism of remifentanil results in the formation of a carboxylic acid metabolite, which in dogs is 1/4600th as potent as remifentanil. Studies in man indicate that all pharmacological activity is associated with the parent compound. The activity of this metabolite is therefore not of any clinical consequence. The half-life of the metabolite in healthy adults is 2 hours. In patients with normal renal function, the time for 95% elimination of the primary metabolite of remifentanil by the kidneys is approximately 7 to 10 hours. Remifentanil is not a substrate for plasma cholinesterase.
Cardiac anaesthesia
The clearance of remifentanil is reduced by approximately 20% during hypothermic (28oC) cardiopulmonary bypass. A decrease in body temperature lowers elimination clearance by 3% per degree centigrade.
Renal impairment
The rapid recovery from remifentanil-based sedation and analgesia is unaffected by renal status.
The pharmacokinetics of remifentanil are not significantly changed in patients with varying degrees of renal impairment even after administration for up to 3 days in the intensive care setting.
The clearance of the carboxylic acid metabolite is reduced in patients with renal impairment. In patients with anuria the half-life of the carboxylic acid metabolite is increased to 30 hours. In intensive care patients with moderate/severe renal impairment, the concentration of the carboxylic acid metabolite is expected to reach approximately 100-fold the level of remifentanil at steady-state. The available clinical data demonstrates that accumulation of the metabolite does not result in clinically relevant p-opioid effects even after administration of remifentanil infusions for up to 3 days in these patients. There are no data available on the safety and pharmacokinetic profile of the metabolite following infusions of Remifentanil for durations greater than 3 days.
There is no evidence that remifentanil is extracted during renal replacement therapy.
The carboxylic acid metabolite is extracted during haemodialysis by at least 30%.
Hepatic impairment
The pharmacokinetics of remifentanil are not changed in patients with severe hepatic impairment awaiting liver transplant, or during the anhepatic phase of liver transplant surgery. Patients with severe hepatic impairment may be slightly more sensitive to the respiratory depressant effects of remifentanil. These patients should be closely monitored and the dose of remifentanil should be titrated to the individual patient need.
Paediatric patients
The average clearance and steady state volume of distribution of remifentanil are increased in children and decline to adolescents values by age 17. The values of these parameters in new born infants are approximately twice those of adolescents. The elimination half-life of remifentanil in new born infants is not significantly different from that of adolescents. Changes in analgesic effect after changes in infusion rate of remifentanil should be rapid and similar to those seen in adolescents. The pharmacokinetics of the carboxylic acid metabolite in children aged 2 to 11 years and adolescents aged 12 to 17 years are similar to those seen in adults after correcting for differences in body weight.
Elderly
The clearance of remifentanil is slightly reduced in elderly patients (>65 years) compared to young patients. The pharmacodynamic activity of remifentanil increases with increasing age. Elderly patients have a remifentanil EC50 for formation of delta waves on the electroencephalogram (EEG) that is 50% lower than young patients; therefore, the initial dose of remifentanil should be reduced by 50% in elderly patients and then carefully titrated to meet the individual patient need.
5.3 Preclinical safety data
Remifentanil, like some other fentanyl analogues, produced increases in action potential duration (APD) in dog isolated Purkinje fibres.
There were no effects at a concentration of 0.1 micromolar (38 ng/ml). Effects were seen at a concentration of 1 micromolar (377 ng/ml), and were statistically significant at a concentration of 10 micromolar (3770 ng/mL). These concentrations are 12-fold and 119-fold respectively the highest likely free concentrations (or 3-fold and 36- fold respectively, the highest likely whole blood concentrations) following the maximum recommended therapeutic dose.
Acute toxicity
Expected signs of p-opioid intoxication were observed in non-ventilated mice, rats, and dogs after large single bolus intravenous doses of remifentanil. In these studies, the most sensitive species, the male rat, survived following administration of 5 mg/kg. Hypoxia-induced brain microhaemorrhages observed in dogs were reversed within 14 days after completion of dosing.
Repeat dose toxicity
Bolus doses of remifentanil administered to non-ventilated rats and dogs resulted in respiratory depression in all dose groups, and in reversible brain microhaemorrhages in dogs. Subsequent investigations showed that the microhaemorrhages resulted from hypoxia and were not specific to remifentanil. Brain microhaemorrhages were not observed in infusion studies in non-ventilated rats and dogs because these studies were conducted at doses that did not cause severe respiratory depression.
It is to be derived from preclinical studies that respiratory depression and associated sequelae are the most likely cause of potentially serious adverse events in humans.
Intrathecal administration to dogs of the glycine formulation alone (i.e. without remifentanil) caused agitation, pain, and hind limb dysfunction and incoordination. These effects are believed to be secondary to the glycine excipient. Because of the better buffering properties of blood, the more rapid dilution, and the low glycine concentration of the Remifentanil formulation, this finding has no clinical relevance for intravenous administration of Remifentanil.
Reproductive toxicity studies
Remifentanil reduced fertility in male rats after daily injection for at least 70 days. A no-effect dose was not demonstrated. Fertility was not affected in female rats. Teratogenic effects were not seen in rats or rabbits. Administration of remifentanil to rats throughout late gestation and lactation did not significantly affect the survival, development, or reproductive performance of the Fi generation.
Placental and milk transfer
Placental transfer studies in rats and rabbits showed that pups are exposed to remifentanil and/or its metabolites during growth and development. Remifentanil-related material is transferred to the milk of lactating rats. In a human clinical trial, the concentration of remifentanil in foetal blood was approximately 50% of that in maternal blood. The foetal arterio-venous ratio of remifentanil concentrations was approximately 30%, suggesting metabolism of remifentanil in the new born infant.
Genotoxicity
Remifentanil did not yield positive findings in a series of in vitro and in vivo genotoxicity tests, except in the in vitro mouse lymphoma tk assay, which gave a positive result with metabolic activation. Since the mouse lymphoma
results could not be confirmed in further in vitro and in vivo tests, treatment with remifentanil is not considered to pose a genotoxic hazard to patients.
Carcinogenicity
Long-term carcinogenicity studies were not performed.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Glycine.
Hydrochloric acid 37% (for pH adjustment).
6.2 Incompatibilities
This medicinal product must not be mixed with other medicinal product except those mentioned in section 6.6.
It should not be admixed with lactated Ringer’s solution for injection or lactated Ringer’s and glucose 50 mg/ml (5%) solution for injection. Remifentanil should not be mixed with propofol in the same intravenous admixture solution.
Administration of Remifentanil into the same intravenous line with blood/serum/plasma is not recommended as non-specific esterase in blood products may lead to the hydrolysis of remifentanil to its inactive metabolite.
Remifentanil should not be mixed with other therapeutic agents prior to administration.
6.3 Shelf life
3 years.
Chemical and physical in-use stability of the reconstituted solution has been demonstrated for 24 hours at 25° C.
Chemical and physical-in-use stability of the diluted solution has been demonstrated for 4 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution /dilution has taken place in controlled and validated aseptic conditions.
6.4 Special precautions for storage
Do not store above 25°C.
For storage conditions of the reconstituted/diluted medicinal product, see section 6.3.
6.5 Nature and contents of container
5 ml vial (type I colourless glass) of remifentanil 2 mg with a chlorobutyl stopper and a flip-off cap.
Packs of 1, 5, 10, 20, 25 and 50 vials.
Not all pack sizes may be marketed
6.6 Special precautions for disposal and other handling
Remifentanil should be prepared for intravenous use by adding 2 ml of diluent to give a reconstituted solution with a concentration of 1mg/ml remifentanil.
The reconstituted solution is clear, colourless, and practically free from particulate material.
After reconstitution, visually inspect the product (where the container permits) for particulate material, discolouration or damage of container. Discard any solution where such defects are observed. Reconstituted product is for single use only. Any unused material should be discarded.
Remifentanil should not be administered by manually-controlled infusion without further dilution to concentrations of 20 to 250 pg/ml (50 pg/ml is the recommended dilution for adults and 20 to 25 pg/ml in paediatric patients aged 1 year and over).
Remifentanil should not be administered by TCI without further dilution (20 to 50 pg/ml is the recommended dilution for TCI).
The dilution is dependent upon the technical capability of the infusion device and the anticipated requirements of the patient.
One of the following I.V. fluids listed below should be used for dilution:
- Water for injections
- Glucose 50 mg/ml (5 %) solution for injection,
- Glucose 50 mg/ml (5 %) and sodium chloride 9 mg/ml (0.9%) solution for injection,
- Sodium chloride 9 mg/ml (0.9 %) solution for injection,
- Sodium chloride 4.5 mg/ml (0.45 %) solution for injection.
After dilution, visually inspect the product to ensure it is clear, colourless, practically free from particulate matter and the container is undamaged. Discard any solution where such defects are observed.
Any unused product or waste material should be disposed of in accordance with local requirements.
Remifentanil has been shown to be compatible with the following intravenous fluids when administered into a running IV catheter:
- Lactated Ringer’s solution for injection,
- Lactated Ringer’s and glucose 50 mg/ml (5 %) solution for injection.
Remifentanil has been shown to be compatible with propofol when administered into a running IV catheter.
7 MARKETING AUTHORISATION HOLDER
Generics [UK] Limited t/a Mylan
Station Close
Potters Bar
Hertfordshire
EN6 1TL
8 MARKETING AUTHORISATION NUMBER(S)
PL 04569/1052
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
30/01/2012
10 DATE OF REVISION OF THE TEXT
04/08/2014